Physician profile
Timothy James Derego
NPI 1013756154
$1,596.90
in general payments reported to CMS, 2019-2025
19 companies · $1,111 in 2025
The $1,111 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $486 · 2025: $1,111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,596.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $471.56 | 2024-2025 | Xifaxan |
| Genzyme Corporation | $276.81 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82.32 | 2024-2025 | Eohilia, Entyvio |
| Boston Scientific Corporation | $74.97 | 2024 | Sentinel |
| Janssen Biotech, INC. | $73.16 | 2025 | Tremfya |
| Phathom Pharmaceuticals, INC. | $72.10 | 2025 | Voquezna |
| Celltrion USA INC. | $70.18 | 2025 | Vegzelma |
| Lilly USA, LLC | $62.55 | 2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $58.79 | 2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $55.48 | 2025 | |
| Ardelyx, INC. | $52.76 | 2024-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $47.92 | 2024-2025 | Resmetirom, Rezdiffra |
| Abbvie INC. | $43.38 | 2024-2025 | |
| Braintree Laboratories, INC. | $38.96 | 2024-2025 | Sutab, Suflave |
| Aimmune Therapeutics, INC. | $34.99 | 2025 | Vowst |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $23.56 | 2025 | |
| Vivus LLC | $21.66 | 2024 | Qsymia |
| Pfizer INC. | $21.26 | 2025 | |
| Merck Sharp & Dohme LLC | $14.49 | 2024 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Derego listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.